What is ARA-290?
ARA-290 (cibinetide) is an 11-amino-acid peptide engineered from a region of erythropoietin (EPO).
How does ARA-290 work?
It activates a tissue-protective receptor linked to EPO without stimulating red-blood-cell production.
What are researchers studying?
- ●Small-fiber neuropathy in sarcoidosis
- ●Nerve damage in diabetes models
- ●Tissue protection after injury
Where does the evidence stand?
Studied in small human trials. Not approved by the FDA.
Quick facts
- Research area
- Immune
- Also known as
- ARA290, Cibinetide
- Third-party lab results
- 2 published COAs →
- Tested vendors tracking it
- 2 vendors →
Recent peer-reviewed research
The most relevant ARA-290 studies from the last three years, via PubMed (U.S. National Library of Medicine).
- Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain ManagementCurrent pain and headache reports · 2026 Aug 24 · PubMed ↗
- Immunometabolic dysregulation drives selective executive cognitive dysfunction in male db/db miceNeurobiology of disease · 2026 Jun 1 · PubMed ↗
Related research guides
Every Monday: the week's price drops and restocks, new third-party lab results, and a plain-English research guide with the latest studies. No spam — unsubscribe anytime.
This guide summarizes published research for educational purposes only. It is not medical advice and does not describe how to use ARA-290. Citations link to PubMed and are listed for reference — we haven't reviewed or endorsed their findings. Products referenced on The Peptide Audit are sold by third parties for laboratory research use only and are not for human consumption.